pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT
LAVA Therapeutics N.V is a pharma organization headquartered in Utrecht, NL. It trades on NYSE under ticker LKFT. Primary therapeutic focus areas include Cystic Fibrosis, Rheumatoid Arthritis, Ulcerative Colitis, Idiopat
Phase 2 · small molecule · Dermatomyositis
GLPG3667 is a small-molecule therapeutic candidate developed by Lakefront Biotherapeutics NV for the treatment of dermatomyositis, a rare autoimmune inflammatory muscle disease. The program (internal code GLPG3667-CL-214) has completed Phase 2 clinical evaluation as of May 2026. The mechanism of action and specific mol
Internal code GLPG3667-CL-214
GLPG3667 is a small-molecule therapeutic candidate developed by Lakefront Biotherapeutics NV for the treatment of dermatomyositis, a rare autoimmune inflammatory muscle disease. The program (internal code GLPG3667-CL-214) has completed Phase 2 clinical evaluation as of May 2026. The mechanism of action and specific molecular target have not yet been disclosed. Lakefront is advancing the program independently without a disclosed partnership arrangement. The completion of Phase 2 represents a significant milestone in the clinical development pathway, positioning the candidate for potential advancement to Phase 3 evaluation, though the timing and design of subsequent studies remain undisclosed. The competitive landscape for dermatomyositis includes multiple candidates in Phase 2 and Phase 3 development, as well as approved therapies, indicating an active therapeutic area with multiple approaches under investigation.
Dermatomyositis is a rare autoimmune myopathy characterized by muscle weakness and distinctive skin manifestations, with limited treatment options and significant unmet medical need. Current standard-of-care therapies often involve corticosteroids and immunosuppressants, which carry substantial side-effect burdens and variable efficacy. The disease affects quality of life significantly and can lead to progressive disability and mortality if inadequately controlled. GLPG3667's advancement to Phase 2 completion suggests potential clinical benefit in this underserved patient population. The competitive landscape reveals substantial pharmaceutical interest in dermatomyositis, with multiple mechanisms under investigation including JAK inhibitors, monoclonal antibodies, and cell therapies, indicating recognition of the commercial and medical opportunity. Successful development of GLPG3667 could capture meaningful market share in a disease area where treatment options remain limited and patient populations are seeking improved efficacy and tolerability profiles. The rare disease designation typically provides regulatory incentives including accelerated pathways and extended market exclusivity, enhancing commercial attractiveness.
Drug Class: Small-molecule immunomodulator (specific class not yet disclosed)
Modality: Small molecule
Mechanism of Action: Not yet disclosed
Molecular Target: Not yet disclosed
Route of Administration: Not yet disclosed
Related Therapies: The competitive space includes JAK inhibitors (baricitinib, approved JAK inhibitor from The First People's Hospital of Lianyungang), monoclonal antibodies (anifrolumab from AstraZeneca, ARGX-117-2301 from argenx), immunomodulators (lenabasum from Corbus Pharmaceuticals), and cell therapies (CAR-T approaches from Chongqing Precision Biotech). First approval and patent status information are not yet disclosed for GLPG3667.
Also known as: DM, dermatopolymyositis, adult dermatomyositis, Amyopathic dermatomyositis
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
ClinicalTrials.gov lists 113 registered studies for Dermatomyositis (AACT aggregate).
Phase breakdown: NA (40), PHASE2 (32), PHASE3 (13), PHASE1 (8), PHASE2/PHASE3 (8), EARLY_PHASE1 (5), PHASE1/PHASE2 (4), PHASE4 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0016367), Orphanet — dermatomyositis, NCT00001261, NCT00001265, NCT00001331, NCT00001421, NCT00004357, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 enrollment and conduct
Phase 2 trial NCT05695950 was conducted to evaluate GLPG3667 in dermatomyositis patients.
Phase 2 completion
Phase 2 program completed as of May 14, 2026.
Phase 3 initiation (expected)
Timing and design of Phase 3 development not yet disclosed.
The dermatomyositis therapeutic landscape includes multiple competing approaches across development stages. JAK inhibitors represent an established mechanism with baricitinib in Phase 2 development (Pari Pharma GmbH) and an approved JAK inhibitor from The First People's Hospital of Lianyungang. Monoclonal antibody approaches include anifrolumab (AstraZeneca AB, Phase 3), ARGX-117-2301 (argenx, Phase 2), and human immunoglobulin G (CSL Behring GmbH, Phase 3). Small-molecule immunomodulators include lenabasum 20 mg (Corbus Pharmaceuticals Holdings, Phase 3) and JBT-101 (Corbus Pharmaceuticals Holdings, Phase 2). Additional Phase 3 candidates include APHP180612 (Pari Pharma GmbH) and C0251010 (Pfizer Australia Pty Ltd). Cell therapy approaches, including CAR-T candidates targeting CD19, BCMA/CD70, and Anti-CD19 UCAR-T cells (all from Chongqing Precision Biotech Co., Ltd), are in early-stage development (Phase 1). GLPG3667's Phase 2 completion positions it in the mid-stage development cohort, with multiple competitors at similar or more advanced stages.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| JAK Inhibitor | The First People's Hospital of Lianyungang | small_molecule | approved |
| human immunoglobulin G | CSL Behring GmbH | small_molecule | phase_3 |
| APHP180612 | Pari Pharma GmbH | small_molecule | phase_3 |
| Anifrolumab, Anifrolumab Placebo | AstraZeneca AB | small_molecule | phase_3 |
| C0251010 | Pfizer Australia Pty Ltd | small_molecule | phase_3 |
| Lenabasum 20 mg | Corbus Pharmaceuticals Holdings | small_molecule | phase_3 |
| ARGX-117-2301 | argenx | small_molecule | phase_2 |
| BARICITINIB | Pari Pharma GmbH | small_molecule | phase_2 |
| JBT-101 | Corbus Pharmaceuticals Holdings | small_molecule | phase_2 |
| Anti-CD19 UCAR-T cells | Chongqing Precision Biotech Co., Ltd | small_molecule | phase_1 |
| BCMA/CD70-targetd CAR-T | Chongqing Precision Biotech Co., Ltd | mab | phase_1 |
| CD19-targetd CAR-T | Chongqing Precision Biotech Co., Ltd | mab | phase_1 |
| PREDNISONE | — | Glucocorticoid receptor agonist | Approved |
| PREDNISOLONE | — | Glucocorticoid receptor agonist | Approved |
| CORTISONE ACETATE | — | Glucocorticoid receptor agonist | Approved |
| USTEKINUMAB | — | Interleukin-23 inhibitor | Phase 3 |
| METHYLPREDNISOLONE | — | Glucocorticoid receptor agonist | Phase 3 |
| METHOTREXATE | — | Dihydrofolate reductase inhibitor | Phase 3 |
| CYCLOSPORINE | — | Cyclophilin A modulator | Phase 3 |
| BREPOCITINIB | — | Tyrosine-protein kinase TYK2 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
FDA Status: Not yet disclosed
EMA Status: Not yet disclosed
PMDA (Japan) Status: Not yet disclosed
NMPA (China) Status: Not yet disclosed
Regulatory Pathway: Dermatomyositis is a rare disease, and GLPG3667 may be eligible for regulatory incentives including orphan drug designation and accelerated development pathways, though specific designations have not been disclosed. The completion of Phase 2 development suggests potential advancement toward Phase 3 and subsequent regulatory submissions, but the timing and jurisdiction of such filings remain undisclosed.
GLPG3667 is a small-molecule therapeutic candidate in development for the treatment of dermatomyositis, a rare autoimmune inflammatory muscle disease characterized by muscle weakness and distinctive skin manifestations.
No, GLPG3667 has not been approved by the FDA. The program has completed Phase 2 clinical evaluation as of May 2026 and regulatory approval status has not been disclosed.
GLPG3667 is developed by Lakefront Biotherapeutics NV, a pharmaceutical company advancing the program independently without a disclosed partnership.
The mechanism of action of GLPG3667 has not yet been disclosed by Lakefront Biotherapeutics. The specific molecular target and biological pathway remain undisclosed.
GLPG3667 has completed Phase 2 clinical evaluation as of May 14, 2026. The program is a small-molecule candidate being developed for dermatomyositis.
GLPG3667 was evaluated in Phase 2 trial NCT05695950. Specific trial design details, enrollment numbers, and results have not yet been disclosed.
Competitors in the dermatomyositis space include JAK inhibitors (baricitinib, approved JAK inhibitor), monoclonal antibodies (anifrolumab, ARGX-117-2301), small-molecule immunomodulators (lenabasum, JBT-101), and cell therapy approaches (CAR-T candidates), with multiple candidates in Phase 2 and Phase 3 development.
GLPG3667 is being developed for dermatomyositis, a rare autoimmune myopathy affecting skeletal muscles and skin.
GLPG3667 is a small-molecule therapeutic candidate.
The expected approval timeline for GLPG3667 has not been disclosed. Phase 3 initiation timing and subsequent regulatory milestones remain undisclosed.
Orphan drug designation status for GLPG3667 has not been disclosed, though dermatomyositis qualifies as a rare disease eligible for such designations.
Safety data from GLPG3667 Phase 2 trials have not yet been publicly disclosed. Efficacy and tolerability results are pending.
Phase 2 trial NCT05695950 has been completed as of May 2026. Availability in ongoing or future trials depends on Phase 3 initiation, which has not yet been announced.
The route of administration for GLPG3667 has not yet been disclosed.
No partnership has been disclosed for GLPG3667. Lakefront Biotherapeutics is advancing the program independently.
Patent status information for GLPG3667 has not been disclosed.
GLPG3667 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Lakefront Biotherapeutics' advancement of GLPG3667 to Phase 2 completion demonstrates commitment to the dermatomyositis indication despite a crowded competitive landscape. The lack of disclosed partnership suggests Lakefront is pursuing independent development, which may indicate confidence in the candidate's differentiation or alternatively reflect early-stage partnership discussions.
Competitive Implications: GLPG3667 enters a Phase 3-dominant competitive environment with multiple candidates in late-stage development. The program's differentiation relative to JAK inhibitors, monoclonal antibodies, and other small-molecule approaches remains unclear pending disclosure of mechanism of action and clinical efficacy data. Success will likely depend on demonstrating superior efficacy, tolerability, or convenience relative to Phase 3 competitors.
Future Catalysts: Key upcoming catalysts include disclosure of Phase 2 efficacy and safety data, announcement of Phase 3 initiation, potential regulatory designation announcements, and competitive readouts from Phase 3 programs in the space. The May 2026 completion milestone suggests Phase 2 data may be disclosed in the near term.
Expected Milestones: Anticipated milestones include Phase 2 data presentation or publication, Phase 3 trial initiation announcement, potential orphan drug or breakthrough therapy designation, and regulatory interactions with global health authorities.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.